Doctors’ warning: Weight loss injections — read this before your next jab
What if the drug helping millions lose weight could also inflame a vital organ without warning? A new update from the U.K.’s Medicines and Healthcare Products Regulatory Agency has reignited debate over the safety of popular weight loss injections such as Wegovy, Ozempic, and Mounjaro, after a rise in reports of acute pancreatitis.
Between 2007 and October 2025, the agency recorded 1,296 cases of pancreatitis linked to GLP-1 receptor agonists and dual GLP-1/GIP drugs, including 19 deaths. The numbers sound alarming, but medical experts stress that perspective matters. Studies suggest pancreatitis occurs in about 0.27% to 2.2% of users, placing it in the “uncommon” category.
Still, regulators say growing use of these medications means even rare side effects can affect more people. In England, Wales, and Scotland alone, around 1.6 million adults used GLP-1 medicines for weight loss between 2024 and 2025.
Related story: Serena Williams shares 31-pound weight loss with GLP-1 drug
Why regulators are paying attention
The MHRA updated its guidance after clusters of real-world cases were reported through the U.K.’s Yellow Card safety monitoring system. Experts say this reflects closer scrutiny rather than panic. According to bariatric surgeon Dr. Mir Ali, the risk is well documented but remains low, and the rise in cases likely mirrors the explosion in prescriptions.
Family physician Dr. David Cutler explains that pancreatitis is a recognized but uncommon risk, and not all studies show a clear increase. He notes that for many patients, the benefits of weight loss and blood sugar control still outweigh potential harms.
Related story: Can eating spicy food help with weight loss? New research reveals surprising effects
Who faces higher risk
Doctors agree that certain factors raise the odds of pancreatitis in people using GLP-1 drugs. These include gallstones, heavy alcohol use, very high triglyceride levels, and a past history of pancreatic disease. Patients with obesity and diabetes often already carry these risks, making careful screening essential.
One bariatric specialist warns that a person combining weekend binge drinking with a GLP-1 injection has a very different risk profile from someone with controlled diabetes and no alcohol intake.
Symptoms you should not ignore
Acute pancreatitis usually causes severe pain in the upper middle abdomen that can spread to the back. It may worsen after eating or lying down and is often accompanied by nausea or vomiting. Fever and chills can appear as inflammation progresses.
Some cases are less obvious. Patients may report bloating, early fullness, or vague discomfort that does not improve with usual remedies. Doctors stress that unusual or intense abdominal pain should never be brushed off while on these medicines.
Not a panic button, but a caution sign
Health experts caution against abandoning treatment without medical advice. Most cases resolve with supportive care and stopping the drug. However, untreated pancreatitis can become life-threatening.
Clinicians are advised to start these medications at low doses, increase gradually, and educate patients clearly about warning signs. Patients are urged to balance benefits with risks and to seek immediate care if symptoms appear.
As weight loss injections become part of everyday healthcare, regulators say the message is simple: powerful medicines demand powerful vigilance. The updated guidance is not meant to scare users but to ensure that safety keeps pace with popularity.
Stay connected with Medical News Pakistan
CLICK HERE TO JOIN our WhatsApp Community for the latest health updates, life-saving medical news, and expert guidance straight to your phone.